Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify potentially actionable genetic alterations and exploit the molecular vulnerabilities of cancer is becoming increasingly difficult. Due to the sporadic nature of somatic cancers, the number of detected variants is exponentially growing, challenging scientists to confidently identify meaningful mutations that could influence or improve decisions in experimental design, at point-of-care, or in drug development.

In this webinar, we will introduce you to the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. Available as a web-based application, this expert-curated resource contains content from over 300,000 real-world clinical oncology cases combined with content from the QIAGEN Knowledge Base, providing gene-level, alteration-level, and disease-level information including clinically observed gene and variant frequencies across diseases. Users can easily search and explore mutational characteristics across genes, synthesize key findings from drug labels, clinical trials, and professional guidelines, and receive detailed annotations for each observed variant. In addition, users can interrogate a bibliography of over 150,000 variant specific PubMed articles and access individual summaries alteration-type specific information written by PhD scientists.

In this webinar, you will learn:

What content sources power HSMD
How to use and apply HSMD for multiple applications, including research, molecular testing, and pharmaceutical development
When and where you can access HSMD